Oricell closes $45 million Series B1 financing

In a second financing within one year, China-based Oricell Therapeutics has announced the close of a $45 million Series B1 investment round. This adds to the $125 million Series B fund that was raised in July 2022.

The round was led by premier global industry investors RTW Investments, and Qatar Investment Authority (QIA), with participation from existing investors, including Qiming Venture Partners and C&D Emerging Industry Equity Investment. The new injection of capital will be utilized primarily to support the company's core product clinical development in the USA.

"We are thrilled with the momentum our team has built over the last several months and look forward to using this funding to further expand our platform and research, commented Oricell’s chairman and chief executive Helen Yang, adding: “This round reflects our investors' recognition of Oricell's ongoing growth and the development of our robust pipeline of ground-breaking therapeutics. We look forward to continuing to help improving the lives of patients in need."